Clinical applications of small-molecule GABAAR modulators for neurological disorders
Bioorganic Chemistry · 2024-12 · 153 · 107983
DOI: 10.1016/j.bioorg.2024.107983 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Bioorganic Chemistry, 2024-12. Verfasst von Guangyong Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, China-Japan Union Hospital of Jilin University, Changchun, China. Hauptthemen laut MEDLINE: Receptors, GABA-A, Nervous System Diseases, Small Molecule Libraries. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 124 Literaturangaben.
Abstract (Originalsprache)
Gamma-aminobutyric acid type A receptor (GABAAR) modulators are crucial in treating neurological and psychiatric disorders, including epilepsy, anxiety, insomnia, and depression. This review examines the synthetic approaches and clinical applications of representative small-molecule GABAAR modulators. Benzodiazepines, such as Diazepam, are well-known positive allosteric modulators (PAMs) that enhance GABAAR function, providing therapeutic effects but also associated with side effects like sedation and dependence. Non-benzodiazepine modulators, including Z-drugs like Zolpidem and Zaleplon, offer improved selectivity for the α1 subunit of GABAAR, reducing some of these side effects. Neurosteroids such as allopregnanolone and its synthetic analogs, including Brexanolone, have emerged as potent GABAAR modulators with applications in conditions like postpartum depression and refractory epilepsy. Advances in molecular biology and pharmacology have facilitated the development of isoform-specific modulators, potentially reducing off-target effects and enhancing therapeutic profiles. Additionally, combining GABAAR modulators with other therapeutic agents has shown promise in enhancing efficacy and minimizing side effects. This review highlights the design strategies, pharmacodynamics, clinical efficacy, and safety profiles of these compounds, emphasizing the opportunities for developing novel GABAAR modulators with improved therapeutic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, China-Japan Union Hospital of Jilin University, Changchun, China.
- Department of Rheumatology and Immunology, China-Japan Union Hospital of Jilin University, Changchun, China.
- Department of Neurosurgery, China-Japan Union Hospital of Jilin University, Changchun, China. Electronic address: neurochen1984@jlu.edu.cn.
- Department of Neurosurgery, China-Japan Union Hospital of Jilin University, Changchun, China. Electronic address: yfw@jlu.edu.cn.
Zitieren
APA
Chen, G., Xu, M., Chen, Z., & Yang, F. (2024). Clinical applications of small-molecule GABAAR modulators for neurological disorders. Bioorganic Chemistry, 153, 107983. https://doi.org/10.1016/j.bioorg.2024.107983
Vancouver
Chen G, Xu M, Chen Z, Yang F. Clinical applications of small-molecule GABAAR modulators for neurological disorders. Bioorganic Chemistry. 2024;153:107983. doi:10.1016/j.bioorg.2024.107983
BibTeX
@article{Chen2024,
author = {Chen, Guangyong and Xu, Meiling and Chen, Zhuo and Yang, Fuwei},
title = {Clinical applications of small-molecule GABAAR modulators for neurological disorders},
journal = {Bioorganic Chemistry},
year = {2024},
volume = {153},
pages = {107983},
doi = {10.1016/j.bioorg.2024.107983}
}
EUVIMED